Pancreatic adenocarcinoma metastatic

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer. April 21, 2025 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies, corresponding with improved survival benefit in patients with melanoma and head and neck cancer at the 2025 Annual Meeting of American Association for Cancer Research (AACR) in Chicago on April 29, 2025. Elizabeth Evans, PhD, Senior VP Discovery and Translational Medicine, will present results of these studies in two presentations. AACR Conference Information: Date:Tuesday, April 29, 2025 Presentation title:Regulating dendritic cells to promote mature tertiary lymphoid structures and enhance anti-tumor immunity. Presentation #3975 Time:9-12 AM CDT/10 AM – 1 PM EDT. Session Title:The Tumor Immune Interplay as a Driver of Progression Presentation title:Neoadjuvant pepinemab enhances DC function associated with mature tertiary lymphoid structures and activity of immune checkpoint blockade in patients with metastatic melanoma. Presentation #6007 Time:2-5 PM CDT/ 3-6 PM EDT. Session Title:Therapeutic Antibodies, Including Engineered Antibodies 2 Access:Posters will be presented in-person on Tuesday, April 29 at McCormick Place Convention Center, Chicago, Illinois, and on AACR 2025 virtual meeting platform at 1:00 PM ET on Friday, April 25, 2025. Previously reported data from these two clinical studies suggest a crucial role of pepinemab to facilitate immune cell interactions within highly organized and robust centers of immunity, called tertiary lymphoid structures, or TLS. By blocking the SEMA4D inhibitory signal to Dendritic Cells (DC), pepinemab allows productive, coordinated interactions between SEMA4D+ T cells, key effector cells capable of eradicating tumors, and DC, regulatory cells that promote immune cell interactions within TLS so as to amplify mature T cell responses. New data will characterize clinical outcomes, biomarkers, and mechanisms of these interactions in patients treated with pepinemab in combination with immune checkpoint therapy. Boosting TLS within tumors is an area of growing excitement because the presence of TLS has been shown to correlate with clinical benefit and positive response to immune checkpoint therapy. A limitation in the field has been identification of safe and effective therapies that can induce formation and harness the potential of TLS to enable durable benefit to patients. Pepinemab may represent a solution to this problem, as our data demonstrate the potential of pepinemab to turn immunologically cold tumors, such as HPV-negative and PD-L1-low head and neck cancer, into hot immune centers by inducing robust and mature TLS. Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of various cancers, showing improved immune and clinical benefit in the preoperative setting compared to standard post surgery adjuvant treatments. Despite these advances, many patients who initially benefit from antibodies that block inhibitory checkpoint molecules (e.g. PD-1, CTLA 4) will progress. More effective combination therapies are needed. Neoadjuvant treatment with pepinemab enhanced TLS maturity and correlated with longer recurrence-free survival when combined with immune checkpoint inhibitors in patients with metastatic melanoma. Evaluation of pepinemab in the neoadjuvant setting for patients with head and neck cancer is ongoing and will be reported at upcoming scientific meeting this Spring. Pepinemab is a humanized IgG4 monoclonal antibody designed to block SEMA4D, which can otherwise bind to plexin-B1 receptors to trigger collapse of the actin cytoskeleton in cells and lead to loss of homeostatic functions of dendritic cells in immune tissue and of astrocytes and other glial cells in the brain. Pepinemab appears to be well-tolerated with a favorable safety profile in multiple clinical trials in different cancer and neurological indications. Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents infiltration and activation of immune cells in tumors and triggers damaging inflammation in neurodegenerative diseases. In oncology, pepinemab is being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma. We believe pepinemab has also given promising results as a monotherapy in the Phase 1b/2 SIGNAL-AD study in Alzheimer’s Disease, and the Company has previously published promising Phase 2 data suggesting a slowing of cognitive decline in Huntington’s disease. Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA. Additional information about the study is available at: clinicaltrials.gov. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. BAVENCIO®/avelumab is provided by Merck KGaA, Darmstadt, Germany, previously as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. The content above comes from the network. if any infringement, please contact us to modify.

Ohio State University Wexner Medical Center 和 James Comprehensive Cancer Center 的研究人員發現，對社會上較弱勢的轉移性胰臟癌病人而言，接受優質照護的機會明顯較低，存活率也較低。 賓夕法尼亞州普利茅斯會議2025年4月10日 /美通社/ -- 2025 年 4 月號的 JNCCN—Journal of the National Comprehensive Cancer Network（《JNCCN 全國綜合癌症網絡期刊》）中的新研究發現，在人們罹患癌症時，由於種族、社會經濟狀況和其他因素，病況存在顯著差異。研究人員使用監測、流行病學和終端結果 (SEER)-Medicare 資料庫，研究 2005-2019 年間診斷出患有 mPDAC 的 14,147 名癌症病人。品質評分是根據接受 1) 符合指引的系統治療、2) 緩和療護，以及 3) 癌症特異性存活期超過 12 個月的病人作決定。 社會脆弱指數 (Social Vulnerability Index; SVI) 指標較高的病人，體驗至少三種質量指標中一個的可能性低 30%。值得注意的是，如果將種族和經濟狀況分開，則無論收入如何，屬於服務不足的種族或民族群體的個人，在體驗一項或多項品質指標方面的可能性降低 25%。剔除種族因素，較低的社會經濟地位讓體驗品質指標的機率降低 34%。 Continue Reading FlyerPage1 Diamantis Tsilimigras 博士是 Ohio State University Wexner Medical Center 及 James Comprehensive Cancer Center 的專家，他表示 「我們的研究結果突顯出需要有針對性的干預，以收窄癌症治療上的差距。聯邦政策可擴大聯邦醫療補助 (Medicaid) 或擴大聯邦醫療保險 (Medicare) 對姑息治療 (Palliative Care) 的承保範圍，從而減少癌症治療的差距。此外，處理健康的社會決定因素的政策（包括為最脆弱的人群提供經濟援助，以及處理與治療建議相關的潛在隱含偏見），可協助解決平等獲得照護方面的差異。」 研究發現，接受適當系統性及/或姑息治療的病人，在確診後存活超過一年的機會較高。研究還發現在 2005 年到 2019 年的研究期間，品質評分和壽命都隨著時間有所改善。 醫學博士、公共衛生學碩士，工商管理碩士 Timothy M. Pawlik 是期刊的資深作者，也是 Ohio State University Wexner Medical Center 及 James Comprehensive Cancer Center 的專家，他補充說：「確保所有病人，不論其背景如何，都能接受符合指引的治療，對於改善轉移性胰臟癌病人的療效非常重要、「我們發現，儘管 NCCN Guidelines 的遵循情況隨著時間的推移有所改善，但轉移性胰腺癌病人在接受與指引相一致的治療方面仍存在顯著差異，這會反過來影響療效。」 Harvard Medical School 外科副教授 Jason S.Gold（不參與這項研究）評論：「越來越多人意識到胰腺癌的治療和結果中存在差異。這項研究通過顯示社會脆弱性 (Social Vulnerability)、未婚地位和較低收入，都與對轉移性胰腺腺癌的質量較低的護理獨立關聯。」 Gold 博士針對這項研究撰寫了一篇較長的回應，可在四月號的 JNCCN 上找到。如欲閱讀 Quality Score Among Patients With Metastatic Pancreatic Adenocarcinoma: Trends, Racial Disparities, and Impact on Outcomes（「轉移性胰腺腺癌患者的品質評分：趨勢、種族差異及對結果的影響差異和對結果的影響」）整個研究，以及相應的 The Last Word（「寫在最後」 ）評論，請前往 JNCCN.org。 關於 JNCCN—Journal of the National Comprehensive Cancer Network 全美有超過 25,000 位腫瘤科醫師和其他癌症照護專業人員閱讀 JNCCN-Journal of the National Comprehensive Cancer Network（《JNCCN 全國綜合癌症網絡期刊》）。這本由同行評審的索引醫學期刊，提供轉譯醫學創新的最新資訊，以及與腫瘤健康服務研究相關的科學研究，包括高品質治療與價值、生物倫理學、比較與成本效益、公共政策，以及支持性治療與存活率的介入性研究。JNCCN 提供有關《NCCN 腫瘤臨床實踐指南》(NCCN Clinical Practice Guidelines in Oncology; NCCN Guildlines®) 的更新、詳細說明指引建議的評論文章、醫療服務研究，以及病人治療中分子觀點的病例報告。JNCCN 由 Harborside/BroadcastMed 出版，請瀏覽 JNCCN.org。要查詢您是否符合 JNCCN 的 免費訂閱資格，請瀏覽 NCCN.org/jnccn/subscribe。請在 x.com/JNCCN 追蹤 JNCCN。 National Comprehensive Cancer Network 簡介 National Comprehensive Cancer Network® (NCCN ®) 正在紀念成立 30 年，這是一個由 領先癌症中心組成的非牟利聯盟，致力於病人護理、研究和教育。NCCN 致力於定義和提高癌症治療的質量，讓癌症治療有效，公平和容易獲得，務求提升所有人的生活質素。《NCCN 腫瘤臨床實踐指南》(NCCN Clinical Practice Guidelines in Oncology; NCCN Guildlines ®」) 為癌症治療、預防和支援服務提供透明、循證和經由專家達成共識的建議。這些建議獲公認為癌症管理臨床指示和政策方面的標準，也是任何醫學領域中可用的最完整且常更新的臨床試驗指南。《NCCN 病人指南》(NCCN Guidelines for Patients®) 在 NCCN Foundation® 的支援下，提供專業的癌症治療資訊，為病人和照顧者提供資訊並賦能。此外，NCCN 還推進腫瘤方面的繼續教育、全球倡議、政策、研究合作與出版事宜。請瀏覽 NCCN.org 以了解更多資訊。 傳媒聯絡： Rachel Darwin 267-622-6624 [email protected] National Comprehensive Cancer Network WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Researchers at The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center found socially vulnerable patients with metastatic pancreatic cancer were significantly less likely to receive key components of quality care and had poorer survival. PLYMOUTH MEETING, Pa., April 9, 2025 /PRNewswire/ -- New research in the April 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network found significant disparities based on race, socioeconomic status, and other factors when it came to quality of care and outcomes for people with metastatic pancreatic adenocarcinoma (mPDAC)—which is associated with very high cancer mortality. The researchers used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to study 14,147 patients who were diagnosed with mPDAC between 2005-2019. Quality scores were determined based on those who received 1) guideline-concordant systemic therapy, 2) palliative care, and 3) a cancer-specific survival of more than 12 months. Continue Reading "Ensuring that all patients... receive guideline-concordant care is important to improve outcomes..." Post this Cover, JNCCN April 2025. Visit JNCCN.org to read the latest issue. Patients with a higher measure on the Social Vulnerability Index (SVI) were 30% less likely to experience at least one of the three quality indicators. Notably, when race and economic status were separated out—individuals who were a member of an underserved racial or ethnic group were 25% less likely to experience one or more quality indicator, regardless of income. Lower socioeconomic status correlated with a 34% lower chance of experiencing a quality indicator, independent of race. "The results of our study highlight the need for targeted interventions to mitigate disparities in cancer care," said lead author Diamantis Tsilimigras, MD, PhD, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center. "Federal policies that expand Medicaid or possibly expand Medicare coverage for palliative care can help reduce disparities. Furthermore, policies that address social determinants of health—including financial aid for the most vulnerable populations as well as understanding and addressing potential implicit biases relative to treatment recommendations—could help address disparities in equal access to care." The study found that patients who did receive appropriate systemic and/or palliative care were more likely to survive longer than a year after being diagnosed. They also found improvement over time, across the study period from 2005 to 2019, in both quality scores and longevity. "Ensuring that all patients, regardless of their background, receive guideline-concordant care is important to improve outcomes for patients with metastatic pancreatic cancer," added senior author Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center. "We found that while adherence to NCCN Guidelines improved over time, there remain significant disparities in the receipt of guideline-concordant care among patients with metastatic pancreatic cancer which can, in turn, affect outcomes." Jason S. Gold, MD, Associate Professor, Surgery, Harvard Medical School—who was not involved in this research—commented: "There is increasing recognition of the persistence of disparities in treatment and outcomes for pancreatic cancer. This study adds to this body of knowledge by showing that social vulnerability, unmarried status, and lower income were all independently associated with lower quality care for metastatic pancreatic ductal adenocarcinoma." Dr. Gold is the author of a longer response to this study that can also be found in the April issue of JNCCN. To read the entire study "Quality Score Among Patients With Metastatic Pancreatic Adenocarcinoma: Trends, Racial Disparities, and Impact on Outcomes" and the corresponding "The Last Word" commentary, visit JNCCN.org. About JNCCN—Journal of the National Comprehensive Cancer Network More than 25,000 oncologists and other cancer care professionals across the United States read JNCCN—Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about innovation in translational medicine, and scientific studies related to oncology health services research, including quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside/BroadcastMed. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit NCCN.org/jnccn/subscribe. Follow JNCCN at x.com/JNCCN. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN ®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information. Media Contact: Rachel Darwin 267-622-6624 [email protected] SOURCE National Comprehensive Cancer Network WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED